Special report: vaccines for the treatment of prostate cancer
BlueCross BlueShield Association

Citation

Authors' conclusions
Other than sipuleucel-T and ProstVAC-VF, other types of vaccines are much less advanced in the types of clinical investigations that have been carried out. These other vaccines still await the initiation and completion of Phase II randomized trials. The prognosis of the current indication of these vaccine products is a median survival between 20 and 30 months. Demonstration of a survival benefit among candidate patients at earlier stages of disease would require much longer periods of study due to the greater baseline prognosis of these patients. However, without such studies, it would be premature to extend the indications for such vaccines (if any are proven to be effective for the current indication).

Timeliness warning
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.

Indexing Status
Subject indexing assigned by CRD

MeSH
Antineoplastic Agents Vacciness; Male; Prostatic Neoplasms

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32011000009

Date abstract record published
19/01/2011